← Back to Search
Rechallenge Strategy In Cancer Therapy
Ekaterina Hanovich, T. Asmis, Michael Ong, D. Stewart
Published 2020 · Medicine
Download PDFAnalyze on Scholarcy
Drug resistance is one of the most important factors limiting the success of systemic anticancer therapy in achieving cure or prolonged overall survival. In clinical practice, resistant disease describes cancer that is found to have progressed since the time of treatment initiation. The term “drug resistant” is often used synonymously with “progressive disease” when referring to a treated tumour. Stopping a treatment at the time of disease progression is the current dominant approach of clinical trial conduct; therefore, available data from clinical trials are routinely not able to provide any information that could challenge this concept of permanent drug resistance. However, drug rechallenge and treatment continuation beyond progression have emerged as potential strategies in the past decade, especially for molecularly targeted agents and immunotherapy. In this review we focussed on rechallenge strategies for chemotherapy, immune therapy and targeted therapy in the main types of cancer.
This paper references
Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.
N. Colombo (2007)
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Renhua Guo (2010)
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
A. Grothey (2008)
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
T. Owonikoko (2012)
The therapeutic promise of the cancer stem cell concept.
N. Frank (2010)
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
L. Fornaro (2012)
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
M. Faehling (2013)
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
F. Maindrault-Goebel (2004)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
X. Le (2018)
Phase II study of docetaxel re‐treatment in docetaxel‐pretreated castration‐resistant prostate cancer
G. di Lorenzo (2011)
Trastu - zumab beyond progression in human epidermal growth factor receptor 2 - positive advanced breast cancer : a German Breast Group 26 / Breast International Group 0305 study
G vonMinckwitz (2009)
Phase II study of docetaxel re-treatment in docetaxelpretreated castration-resistant prostate cancer
G Di Lorenzo (2011)
Clinical practice guidelines in oncology. Soft tissue sarcoma. Version
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
A. de Gramont (2007)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H. Yokouchi (2006)
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
G. Cancello (2007)
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
R. Adams (2011)
Clonal evolution in cancer
Jesse J Salk (2010)
Strategies to improve the management of depression in primary care.
J. Unützer (2012)
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.
A. Patrikidou (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
K. Nishie (2012)
Does Gefitinib Re-challenge or Treatment Beyond Progression (TBP) Prolong Survival of NSCLC Patients? - Real World Evidence from Gefitinib Treatment Responders
Yoshinobu Namba (2012)
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology
H Asahina (2010)
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
G. von Minckwitz (2009)
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
K. Blackwell (2012)
Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.
P. Postmus (1987)
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
C. Tournigand (2006)
Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.
M. Zhuo (2014)
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
A. Wong (2008)
Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
Maiko Niki (2018)
Unmaintained remissions in multiple myeloma.
R. Alexanian (1978)
Maintenance chemotherapy for advanced Hodgkin's disease in remission.
R. C. Young (1973)
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
Mona-Elisabeth R Revheim (2013)
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy.
Y. Tomizawa (2010)
Cancer Care Ontario's Gastrointestinal Disease Site Group. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis
S R Berry
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
C. Robert (2013)
Rational indication for docetaxel rechallenge in metastatic castration‐resistant prostate cancer
M. Heck (2012)
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
D. Stewart (2010)
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel
D. Trump (2008)
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
M. Campiglio (2011)
Intermittent chemotherapy in patients with metastatic androgen‐independent prostate cancer
T. Beer (2008)
Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
R. A. Cox (2008)
Oxali - platin reintroduction in patients previously treated with leucovorin , fluorouracil and oxaliplatin for metastatic colorectal cancer
F Maindrault-Goebel (2004)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
J. Bennouna (2013)
Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer
A. Grothey (2010)
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
S. Valpione (2018)
Clinical practice guidelines in oncology . Soft tissue sarcoma . Version 2013 . 1 . 2013 [ Internet ]
Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study
Jean-Christophe Eymard (2010)
Drug rechallenge and treatment beyond progression—implications for drug resistance
E. A. Kuczynski (2013)
Impact of imatinib plus best supportive care in imatinib- and sunitinib-exposed patients with refractory advanced gastrointestinal stromal tumor.
A. Sawaki (2010)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
Does Gefitinib Re-challenge or Treatment Beyond Progression (TBP) Prolong Survival of NSCLC Patients? - Real World Evidence from Gefitinib Treatment Responders
Y. Namba (2012)
Understanding Rechallenge and Resistance in the Tyrosine Kinase Inhibitor Era: Imatinib in Gastrointestinal Stromal Tumor
M. Agulnik (2014)
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
B. Šeruga (2008)
ZD1839) after acquisition of resistance
T Kurata (2004)
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
A. Le Cesne (2010)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
D. Tripathy (2004)
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
M. Schreuer (2017)
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
H. Asahina (2010)
who previously controlled to gefitinib : a single - arm , open - label , phase II study
R Guo (2012)
A study of IRESSA treatment beyond progression in addition to chemotherapy versus chemotherapy alone (IM-PRESS)
American College of Chest Physicians. Small cell lung cancer
GR Simon (2003)
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
Jean-Marc Extra (2010)
Alimita: summary of product characteristics
Chemotherapy resistance and retreatment: a dogma revisited.
A. Naing (2010)
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
V. Chiarion-Sileni (2014)
Intermittent endocrine therapy for advanced prostate cancer
L. Klotz (1986)
Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.
S. Berry (2015)
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
T. Kurata (2004)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
N. Hanna (2004)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
J. Pignon (2001)
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
G. Oxnard (2010)
Random - ized study of lapatinib alone or in combination with trastuzumab in women with ErbB 2 - positive , trastuzumab - refractory metastatic breast cancer
KL Blackwell (2010)
Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.
M. Ryu (2013)
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
S. Yano (2005)
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
G. Tonini (2013)
Rechallenge with docetaxel as second - line chemotherapy in patients with metastatic hormone refractory prostate cancer ( HRPC ) after previous docetaxel : a population based analysis
TM Beer (2008)
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
M. Hejna (1998)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
L. Gandhi (2018)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
D. Cunningham (2004)
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
B. Chibaudel (2009)
Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population
P. Reichardt (2011)
OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study
M. Dong (2006)
Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment
S. J. Yoo (2012)
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial
TS Maughan (2003)
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
A. Becker (2011)
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
C. Palmieri (2010)
Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance.
S. Cara (2001)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini (2012)
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
A. Italiano (2011)
Clinical outcome for continuous versus intermittent chemotherapy for unresectable metastatic colorectal cancer: Comparative analysis after first-line therapy.
N. Abdallah (2018)
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.
A. Bernard-Tessier (2018)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
K. Blackwell (2010)
Rechallenge with pemetrexedbased chemotherapy improves the survival of patients with advanced non-squamous nonsmall-cell lung cancer
ML Zhuo (2014)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases
K. Fujita (2018)
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
J. Blay (2007)
Compari - son of intermittent and continuous palliative chemotherapy for advanced colorectal cancer : a multicentre randomised trial
A deGramont (2003)
Phase II study of docetaxel retreatment in docetaxel - pretreated castration - resistant prostate can
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
M. Socinski (2018)
Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer.
H. Muss (1987)
A pooled analysis of 2,618 patients treated with trastuzumab beyond progression for advanced breast cancer
F Petrelli (2013)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
L. Saltz (2000)
Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
I. Oh (2012)
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
J. Ansari (2008)
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
D. Lee (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
G. Scagliotti (2008)
What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer? A review of the data.
J. Krell (2009)
Intermittent chemotherapy in metastatic androgen-independent prostate cancer
T. Beer (2003)